title: Evaluation of Multiple Biological Therapies for Ischemic Cardiac Disease.
abstract: The development of cell- and gene-based strategies for regenerative medicine offers a therapeutic option for the repair and potential regeneration of damaged cardiac tissue post-myocardial infarction (MI). Human umbilical cord subepithelial cell-derived stem cells (hUC-SECs), human bone marrow-derived mesenchymal stem cells (hBM-MSCs), and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), all derived from human tissue, have been shown to have in vitro and in vivo therapeutic potential. Additionally, S100a1, VEGF165, and stromal-derived factor-1α (SDF-1α) genes all have the potential to improve cardiac function and/or effect adverse remodeling. In this study, we compared the therapeutic potential of hBM-MSCs, hUC-SECs, and hiPSC-CMs along with plasmid-based genes to evaluate the in vivo potential of intramyocardially injected biologics to enhance cardiac function in a mouse MI model. Human cells derived from various tissue types were expanded under hypoxic conditions and injected intramyocardially into mice that had undergone left anterior descending (LAD) artery ligation. Similarly, plasmids were also injected into three groups of mice after LAD ligation. Seven experimental groups were studied in total: (1) control (saline), (2) hBM-MSCs, (3) hiPSC-CMs, (4) hUC-SECs, (5) S100a1 plasmid, (6) VEGF165 plasmid, and (7) SDF-1α plasmid. We evaluated echocardiography, hemodynamic catheterization measurements, and histology at 4 and 12 weeks post-biologic injection. Significant improvement was observed in cardiac function and contractility in hiPSC-CM and S100a1 groups and a significant reduction in left ventricle scar within the hUC-SEC group and a slight improvement in the SDF-1α and VEGF165 groups compared to the control group. These results demonstrate the potential for new biologic therapies to reduce scar burden and improve contractile function.
authors.affiliation: University of Utah School of Medicine, Salt Lake City, UT, USA.
authors.forename: Amalia A
authors.initials: AA
authors.lastname: Winters
authors.forename: Sophia
authors.initials: S
authors.lastname: Bou-Ghannam
authors.forename: Hallie
authors.initials: H
authors.lastname: Thorp
authors.forename: Jose A
authors.initials: JA
authors.lastname: Hawayek
authors.forename: Donald L
authors.initials: DL
authors.lastname: Atkinson
authors.forename: Courtney E
authors.initials: CE
authors.lastname: Bartlett
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Silva
authors.forename: Edward W
authors.initials: EW
authors.lastname: Hsu
authors.forename: Alonso P
authors.initials: AP
authors.lastname: Moreno
authors.forename: David A
authors.initials: DA
authors.lastname: Grainger
authors.forename: Amit N
authors.initials: AN
authors.lastname: Patel
mesh_terms: D000818:Animals; D001691:Biological Therapy / Q000379:methods*; D064987:Cell- and Tissue-Based Therapy / Q000379:methods; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology / Q000502:physiology; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000502:physiology; D009203:Myocardial Infarction / Q000628:therapy*